[Comparison of tigecycline and vancomycin activities in an in vitro biofilm model generated with

Halil Aslan1, Nur Yapar

  • 1Evliya Celebi Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Kütahya, Turkey. halilaslan_79@hotmail.com.

Mikrobiyoloji Bulteni
|December 10, 2015
PubMed

Insights

Tigecycline demonstrated superior efficacy compared to vancomycin in eradicating methicillin-resistant Staphylococcus aureus (MRSA) biofilms in an in vitro catheter model. These findings suggest tigecycline as a promising alternative for treating catheter-related infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Intravenous catheters are a primary source of bloodstream infections, often caused by staphylococci.
  • Methicillin-resistant Staphylococcus aureus (MRSA) forms biofilms, complicating treatment, and vancomycin shows limited efficacy against these biofilms.

Purpose of the Study:

  • To compare the in vitro efficacy of tigecycline and vancomycin against MRSA biofilms.
  • To evaluate tigecycline as a potential alternative treatment for catheter-related infections.

Main Methods:

  • Ten clinical MRSA strains were used to create biofilms on silicone discs.
  • Biofilms were exposed to tigecycline and vancomycin using a 24-hour incubation and an antibiotic lock therapy model.
  • Colony-forming unit counts were assessed to determine bacterial reduction.

Main Results:

  • Tigecycline significantly reduced MRSA colony counts more effectively than vancomycin in both 24-hour and antibiotic lock therapy models.
  • No MRSA growth was detected with tigecycline in the antibiotic lock therapy model by day five, while vancomycin showed reduced but persistent growth.
  • Tigecycline exhibited statistically significant superiority over vancomycin from day one to day four in the antibiotic lock therapy model.

Conclusions:

  • Tigecycline demonstrates a higher efficacy in reducing MRSA biofilm formation on silicone discs compared to vancomycin.
  • Tigecycline presents a potential alternative treatment option for catheter-related infections caused by MRSA biofilms.